The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g.,…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
Clarivate Epidemiology's coverage of psoriatic arthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for each…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key psoriatic arthritis patient populations covering 171 countries and…
Psoriatic Arthritis
Psoriatic Arthritis